TickerFacts.

Indivior Pharmaceuticals, Inc. (INDV): Revenue

Annual figures by period end, from SEC filings.

$1.24B
Year ended 2025-12-31
$1.33B
Trailing 12 months to 2026-06-30
+11.2%
3-year compound annual growth
2022-12-31: $901.00M2023-12-31: $1.09B2024-12-31: $1.19B2025-12-31: $1.24B$1.24B
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$1.24B+4.3%2026-02-26, From 2025-01-01
2024-12-31$1.19B+8.7%2026-02-26, From 2024-01-01
2023-12-31$1.09B+21.3%2026-02-26, From 2023-01-01
2022-12-31$901.00Mn/a2025-03-03, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Indivior Pharmaceuticals, Inc. (INDV)2025-12-31$1.24B+4.3%
Prestige Consumer Healthcare Inc. (PBH)2026-03-31$1.09B-4.3%
Acadia Pharmaceuticals Inc (ACAD)2025-12-31$1.07B+11.9%
Alkermes plc. (ALKS)2025-12-31$1.48B-5.2%
Phibro Animal Health Corp (PAHC)2026-06-30$1.52B+17.1%
Madrigal Pharmaceuticals, Inc. (MDGL)2025-12-31$958.40M+432.1%
Ionis Pharmaceuticals Inc (IONS)2025-12-31$943.71M+33.8%
PTC Therapeutics, Inc. (PTCT)2025-12-31$1.73B+114.5%
ANI Pharmaceuticals Inc (ANIP)2025-12-31$883.37M+43.8%

Compare INDV, PBH, ACAD, ALKS side by side · Screen every company in Pharmaceutical Preparations ↗